Literature DB >> 31763992

Medications for opioid use disorders: clinical and pharmacological considerations.

Nora D Volkow, Carlos Blanco.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 31763992      PMCID： PMC6934219          DOI： 10.1172/JCI134708

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  15 in total

Review 1.  Dynorphin, Dysphoria, and Dependence: the Stress of Addiction.

Authors:  Charles Chavkin; George F Koob
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

Review 2.  Sensing and expressing homeostatic synaptic plasticity.

Authors:  Mark M Rich; Peter Wenner
Journal:  Trends Neurosci       Date:  2007-01-30       Impact factor: 13.837

Review 3.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

4.  [Proposal for improving the integration of drug dependencies in psychiatric nosology].

Authors:  J Pérez de los Cobos; F Batlle; M Casas
Journal:  Actas Luso Esp Neurol Psiquiatr Cienc Afines       Date:  1996 Mar-Apr

Review 5.  Management of opioid use disorder in the USA: present status and future directions.

Authors:  Carlos Blanco; Nora D Volkow
Journal:  Lancet       Date:  2019-03-14       Impact factor: 79.321

Review 6.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

Review 7.  Neurobiology of addiction: a neurocircuitry analysis.

Authors:  George F Koob; Nora D Volkow
Journal:  Lancet Psychiatry       Date:  2016-08       Impact factor: 27.083

8.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

9.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

Review 10.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702
View more
  4 in total

1.  Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.

Authors:  Nicholas Lintzeris; Adrian J Dunlop; Paul S Haber; Dan I Lubman; Robert Graham; Sarah Hutchinson; Shalini Arunogiri; Victoria Hayes; Peter Hjelmström; Agneta Svedberg; Stefan Peterson; Fredrik Tiberg
Journal:  JAMA Netw Open       Date:  2021-05-03

2.  Metabolomics reveals biomarkers of opioid use disorder.

Authors:  Reza Ghanbari; Yuanyuan Li; Wimal Pathmasiri; Susan McRitchie; Arash Etemadi; Jonathan D Pollock; Hossein Poustchi; Afarin Rahimi-Movaghar; Masoumeh Amin-Esmaeili; Gholamreza Roshandel; Amaneh Shayanrad; Behrouz Abaei; Reza Malekzadeh; Susan C J Sumner
Journal:  Transl Psychiatry       Date:  2021-02-04       Impact factor: 6.222

3.  Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.

Authors:  Milja Heikkinen; Heidi Taipale; Antti Tanskanen; Ellenor Mittendorfer-Rutz; Markku Lähteenvuo; Jari Tiihonen
Journal:  Addiction       Date:  2022-02-07       Impact factor: 7.256

4.  An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.

Authors:  Carrie M Mintz; Ned J Presnall; Kevin Y Xu; Sarah M Hartz; John M Sahrmann; Laura J Bierut; Richard A Grucza
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.